Evidence map›Paper›PMID 38203360›Full record

ArticleInternational journal of molecular sciences2023

Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma.

Cita Zupanc, Alenka Franko, Danijela Štrbac, Viljem Kovač, Vita Dolžan, Katja Goričar

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Cita ZupancMilitary Medical Unit-Slovenian Army, 1000 Ljubljana, Slovenia.
Alenka FrankoFaculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Danijela ŠtrbacFaculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-0041-8859
Viljem KovačFaculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Vita DolžanPharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0001-6707-6649
Katja GoričarPharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0001-5673-4458
University of Ljubljana · SI

Funding

Slovenian Research Agency P1-0170, L3-8203 and L3-2622
6 · The paper itself

Abstract

Calretinin is a promising diagnostic biomarker for malignant mesothelioma (MM), but less is known about its prognostic role. Our aim was to evaluate the association between serum calretinin concentration or genetic factors and the survival or outcome of cisplatin-based chemotherapy in MM. Our study included 265 MM patients. Serum calretinin concentration was determined using ELISA. Patients were genotyped for seven polymorphisms in

Indexed as

CisplatinMesothelioma, MalignantBiomarkersCalbindin 2HumansPrognosisBiomarkersCALB2 protein, humanCalbindin 2CisplatinbiomarkerCALB2calretininmalignant mesotheliomapolymorphism

Identifiers

PMID38203360
PMCPMC10778798
OpenAlexW4390112963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.